Bone marrow or hematopoietic stem cell transplantation (HSCT) is a curative treatment option for hematological malignancies, several non-malignant hematological diseases, and severe combined immune deficiencies. However, graft-versus-host disease (GVHD) represents a major complication following allogeneic HSCT which compromises the survival and quality-of-life of the recipient, thus limiting the wider application of this procedure. Basic research has significantly increased our understanding of the underlying mechanisms of this complication. Consequently, development of pharmaceutical, immune, and cellular therapies has improved the outcome of HSCT, however, GVHD still remains a significant clinical problem.
The recent decade has witnessed rapid development of immune and cellular therapies for solid cancers and hematological malignancies. Chimeric antigen receptor T cells (CAR T) are rapidly changing the landscape of treatment options for leukemia, lymphoma, and many other diseases. Thus, research and the practice of HSCT must incorporate these novel technologies in this revolutionary era. This Frontiers Research Topic aims to gather the latest insights on preclinical studies of HSCT, highlighting opportunities and challenges, and to shed light on the future of HSCT in the context of CAR T therapy. Mouse models of HSCT, CAR T therapy, and infectious complications are the focus of this collection with an emphasis on the biological relevance to the clinic and translational potential.
We welcome authors to submit either a Review, Methods, and or Original Research articles on the following, and related, subtopics:
1. Mouse models of acute and chronic GVHD and their cellular therapies;
2. Mouse models of graft-versus-leukemia (GVL) and CAR T therapy;
3. Xenogeneic mouse models for the study of GVHD, GVL, and CAR T therapy;
4. Mouse models for the study of microbiota and metabolomics following HSCT;
5. Mouse models of infectious and non-infectious complications in the context of HSCT;
6. Mouse models of autologous HSCT;
Bone marrow or hematopoietic stem cell transplantation (HSCT) is a curative treatment option for hematological malignancies, several non-malignant hematological diseases, and severe combined immune deficiencies. However, graft-versus-host disease (GVHD) represents a major complication following allogeneic HSCT which compromises the survival and quality-of-life of the recipient, thus limiting the wider application of this procedure. Basic research has significantly increased our understanding of the underlying mechanisms of this complication. Consequently, development of pharmaceutical, immune, and cellular therapies has improved the outcome of HSCT, however, GVHD still remains a significant clinical problem.
The recent decade has witnessed rapid development of immune and cellular therapies for solid cancers and hematological malignancies. Chimeric antigen receptor T cells (CAR T) are rapidly changing the landscape of treatment options for leukemia, lymphoma, and many other diseases. Thus, research and the practice of HSCT must incorporate these novel technologies in this revolutionary era. This Frontiers Research Topic aims to gather the latest insights on preclinical studies of HSCT, highlighting opportunities and challenges, and to shed light on the future of HSCT in the context of CAR T therapy. Mouse models of HSCT, CAR T therapy, and infectious complications are the focus of this collection with an emphasis on the biological relevance to the clinic and translational potential.
We welcome authors to submit either a Review, Methods, and or Original Research articles on the following, and related, subtopics:
1. Mouse models of acute and chronic GVHD and their cellular therapies;
2. Mouse models of graft-versus-leukemia (GVL) and CAR T therapy;
3. Xenogeneic mouse models for the study of GVHD, GVL, and CAR T therapy;
4. Mouse models for the study of microbiota and metabolomics following HSCT;
5. Mouse models of infectious and non-infectious complications in the context of HSCT;
6. Mouse models of autologous HSCT;
